Zolpidem reduces hippocampal neuronal activity in freely behaving mice: a large scale calcium imaging study with miniaturized fluorescence microscope.
Therapeutic drugs for cognitive and psychiatric disorders are often characterized by their molecular mechanism of action. Here we demonstrate a new approach to elucidate drug action on large-scale neuronal activity by tracking somatic calcium dynamics in hundreds of CA1 hippocampal neurons of pharmacologically manipulated behaving mice. We used an adeno-associated viral vector to express the calcium sensor GCaMP3 in CA1 pyramidal cells under control of the CaMKII promoter and a miniaturized microscope to observe cellular dynamics. We visualized these dynamics with and without a systemic administration of Zolpidem, a GABAA agonist that is the most commonly prescribed drug for the treatment of insomnia in the United States. Despite growing concerns about the potential adverse effects of Zolpidem on memory and cognition, it remained unclear whether Zolpidem alters neuronal activity in the hippocampus, a brain area critical for cognition and memory. Zolpidem, when delivered at a dose known to induce and prolong sleep, strongly suppressed CA1 calcium signaling. The rate of calcium transients after Zolpidem administration was significantly lower compared to vehicle treatment. To factor out the contribution of changes in locomotor or physiological conditions following Zolpidem treatment, we compared the cellular activity across comparable epochs matched by locomotor and physiological assessments. This analysis revealed significantly depressive effects of Zolpidem regardless of the animal's state. Individual hippocampal CA1 pyramidal cells differed in their responses to Zolpidem with the majority (∼ 65%) significantly decreasing the rate of calcium transients, and a small subset (3%) showing an unexpected and significant increase. By linking molecular mechanisms with the dynamics of neural circuitry and behavioral states, this approach has the potential to contribute substantially to the development of new therapeutics for the treatment of CNS disorders.
Janssen Research & Development, LLC, San Diego, California, United States of America.
Tamara
T
Berdyyeva
Inscopix, Palo Alto, California, United States of America.
Stephani
S
Otte
Janssen Research & Development, LLC, San Diego, California, United States of America.
Leah
L
Aluisio
Inscopix, Palo Alto, California, United States of America.
Yaniv
Y
Ziv
Inscopix, Palo Alto, California, United States of America.
Laurie D
LD
Burns
Janssen Research & Development, LLC, San Diego, California, United States of America.
Christine
C
Dugovic
Janssen Research & Development, LLC, San Diego, California, United States of America.
Sujin
S
Yun
Inscopix, Palo Alto, California, United States of America.
Kunal K
KK
Ghosh
Inscopix, Palo Alto, California, United States of America.
Mark J
MJ
Schnitzer
Janssen Research & Development, LLC, San Diego, California, United States of America.
Timothy
T
Lovenberg
Janssen Research & Development, LLC, San Diego, California, United States of America.
Pascal
P
Bonaventure
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D056547:CA1 Region, Hippocampal / Q000166:cytology / Q000378:metabolism; D002118:Calcium / Q000378:metabolism*; D058785:GABA-A Receptor Agonists / Q000494:pharmacology*; D008124:Locomotion / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008856:Microscopy, Fluorescence / Q000379:methods; D057054:Molecular Imaging / Q000379:methods*; D061848:Optical Imaging / Q000379:methods*; D017966:Pyramidal Cells / Q000166:cytology / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology*; D000077334:Zolpidem
D058785:GABA-A Receptor Agonists; D011725:Pyridines; D000077334:Zolpidem; D002118:Calcium